by Elena Iemma | May 13, 2021 | Featured, News
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method...
by Annie De Groot | Mar 27, 2020 | News
March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen...
by Annie De Groot | Jun 28, 2019 | Events
7th Annual Cambridge Healthtech Institute’s Immuno-Oncology Summit Powering Next Generation Targeted Immunotherapies Monday, August 5th – Friday August 9th Westin Boston Waterfront 425 Summer Street Boston, MA 02210 UPDATE: EpiVax Oncology (EO) would like...
by Sarah Moniz | Jun 13, 2018 | Featured, News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
by Annie De Groot | Dec 3, 2017 | Thinking Out Loud -Blog
So, you say, why not? Why wait for Gritstone, BioNtec, Neon or even EpiVax Oncology when you can just DIY? If you can now sequence your own cancer mutanome (for about $5,000), and predict your own mutated epitopes using online tools, why not? Some cancer patients are...